Continued Therapeutic Response Monitoring in Optimal Responders With CML.

摘要

H&O What components are involved in molecular monitoring? SB Molecular monitoring in chronic myelogenous leukemia (CML) has 2 components. The first is the measurement of BCR-ABL1 mRNA levels to assess response to therapy and measure minimal residual disease. Most laboratories use real-time quantitative polymerase chain reaction (PCR) techniques to measure BCR-ABL1 levels of peripheral blood. The second component involves sequencing of the BCR-ABL1 kinase domain to detect kinase inhibitor-resistant mutations. Mutation analysis is usually performed only in cases of suspected inhibitor therapy failure or when there is a rise in BCR-ABL1 levels.